Help Patients Focus on Goals, Not Weight, in Diabetes Care
This transcript has been edited for clarity.
Hi. I'm Dr Priya Jaisinghani, an endocrinologist and obesity medicine specialist. Did you know that losing just 5%-10% of body weight can help improve blood sugar control, insulin sensitivity, and even reduce the need for medication for diabetes?
Research shows that modest weight loss lowers blood sugar, blood pressure, andcholesterol, helping to prevent complications. The secret is small, sustainable changes over time.
Instead of focusing just on the scale, shift the focus to smart goals — specific, measurable, achievable, relevant, and time-bound goals. For example, instead of counseling patients to exercise more, set a goal, such as walk 30 minutes, 5 days a week for the next month. Breaking down goals into realistic steps makes weight loss more attainable and impactful.
Also, encourage patients to build a support team, including exercise physiologists, nutritionists, diabetes educators, and other healthcare professionals who provide guidance, education, and accountability. Small steps can lead to big results.
Stay informed and stay inspired with me, Dr J.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association
CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the presentation of new human clinical data at the 85th Scientific Sessions of the American Diabetes Association (ADA), held in Chicago. The poster, titled 'Uncovering the bidirectional glucose-dependent relationship of insulin and glucagon: a meal-challenge study in patients with Type 1 diabetes,' was presented by Dr. Guillaume Kraft, Research Assistant Professor at Vanderbilt University. The study examined how insulin and glucagon behave when delivered together in a fixed ratio at mealtime in people with Type 1 diabetes. The study builds on earlier preclinical research at Vanderbilt University, where scientists observed that insulin and glucagon might interact differently depending on a person's blood sugar level. In that work, the hormones appeared to shift in dominance—insulin having a stronger effect when glucose was high, and glucagon becoming more influential when glucose was low. This human study explored whether similar patterns could be seen when the two hormones were given together in a single fixed ratio at mealtime to people with Type 1 diabetes, under closely monitored conditions. The clinical trial was led by Dr. Bruce Bode and his team at Atlanta Diabetes Associates involving 15 participants with Type 1 diabetes. The results suggested that combining glucagon with insulin at a single fixed ratio at mealtime may offer protection against hypoglycemia during the post-meal drop in blood sugar—without interfering with key metabolic processes. The combination was well tolerated and showed a favorable safety profile. 'We are grateful to Dr. Kraft and the research team at Vanderbilt, and to Dr. Bode and his team in Atlanta, for advancing this important translational work,' said Dr. David Maggs, co-founder of Abvance Therapeutics. 'This study provides early human insight into how carefully designed glucagon-insulin combinations may offer a new tool for improving the day-to-day safety of intensive insulin therapy.' The results mark the first human data evaluating fixed-ratio co-administration of insulin and glucagon in a mealtime setting and offer early support for Abvance's approach to rationally engineered glucagon analogs. 'Abvance is excited to build on this foundational work as we advance our pipeline of glucagon-based therapies designed to integrate seamlessly into real-world treatment strategies,' added Maggs. About Abvance TherapeuticsAbvance Therapeutics, Inc. is a privately held biotechnology company advancing novel glucagon-based therapies designed to integrate into the lived experience of diabetes care. Founded on research from Vanderbilt University and led by a team with expertise in diabetes therapeutics, drug development, and health technology. For more information visit Media & Investor ContactsEdward Raskined@ Veena Raoveena@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Weight loss in your 40s and 50s can help slash your chronic disease risk, researchers say
Working to lose weight in your 40s and 50s may help to reduce your risk of developing a chronic disease, a new study reveals. Researchers based in the U.K. and Finland say they found health benefits in people who lost an average of 6.5 percent of their body weight in early middle age and maintained that weight loss throughout a period of 12 to 35 years. Those benefits especially include a lessened risk for cardiovascular disease and diabetes as well as an overall lower risk of death from chronic disease. 'The benefits of lifestyle-based weight management are widely discussed even though studies have found it surprisingly difficult to demonstrate health benefits beyond the prevention of diabetes,' University of Helsinki professor Dr. Timo Strandberg said in a statement. Strandberg was the lead author of the study which was published recently in the journal JAMA Network Open, the open-access journal of the American Medical Association. To reach these conclusions, the study tracked and analyzed the health of 23,000 white Europeans who were between the ages of 30 and 50 years old using data from three studies, conducted from 1985 to 1988, from 1964 to 1973, and between 2000 and 2013. They sorted the participants into four groups: people with persistent healthy weight, people who were overweight but became a healthy weight, people who were healthy and became overweight, and people who were overweight the entire time. 'Measurement of weight and height was conducted at a time when surgical and pharmacological weight-loss interventions were nearly nonexistent,' the authors noted. The cause of weight loss was not assessed, but given the age of the participants and lack of diagnosed disease, it was more likely intentional than caused by severe chronic conditions or frailty.' In one study, a reduction in body mass from overweight to normal weight over six years in mid-life was tied to a lower risk of developing chronic diseases. There was also a 48 percent lower risk for chronic illness compared to those who remained overweight, which largely held even after excluding participants who developed diabetes during follow-up. Another study showed a 57 percent risk for chronic illness. A third study, with the longest follow-up period, showed that weight loss in mid-life was associated with a 19 percent reduction in overall mortality. 'I'm certain that overall prevention of overweight and obesity starting in early life is absolutely the best thing to do,' Stranberg told The Independent. 'Our study indirectly proves this by showing that persistent healthy weight over the life-course is best.' He said that he hopes the findings will inspire people to see that lifestyle changes can lead to a longer life. 'This is particularly important today as more people are overweight than when the collection of our research data began 35 years ago,' he said in the statement.
Yahoo
2 hours ago
- Yahoo
UnitedHealth Group (NYSE:UNH) Announces Debt Financing Totalling US$3 Billion
UnitedHealth Group recently completed a substantial debt financing deal, raising $3 billion through the issuance of various Notes. This move comes amid a period of legal settlements, such as the $69 million ERISA case, and operational restructuring, including exploring bids for its Latin American operations. Despite these significant developments, the company's stock price remained relatively flat over the last month, reflecting broader market trends which also showed minimal movement. The dividend increase and shareholder discussions on executive compensation may have subtly influenced sentiment, but overall, these events seemed to align with the market's flat performance. UnitedHealth Group has 1 possible red flag we think you should know about. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. UnitedHealth Group's recent $3 billion debt financing and restructuring efforts, such as evaluating bids for its Latin American operations, are significant developments. While the near-term stock price remained relatively stable amid these changes, over the past five years, the company's total shareholder return, including dividends, was 13.61%. This reflects a steady growth trajectory, although in the last year, UnitedHealth underperformed the US Healthcare industry. The current share price sees a slight discount from the analyst consensus price target of $547.65, which is 28% higher than the present value. Despite recent legal settlements and compensation discussions, the company's aggressive push towards digital tools and Medicare adjustments might bolster future earnings and revenue. UnitedHealth's projected earnings per share and revenue growth is positioned slightly behind broader market expectations over the next few years, yet planned improvements in operational efficiencies could bridge this gap over time. Learn about UnitedHealth Group's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:UNH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
